5 Stocks Pulling The Drugs Industry Downward

Editor's Note: Any reference to TheStreet Ratings and its underlying recommendation does not reflect the opinion of TheStreet, Inc. or any of its contributors including Jim Cramer or Stephanie Link.

One out of the three major indices are trading lower today with the Dow Jones Industrial Average ( ^DJI) trading up 14 points (0.1%) at 16,456 as of Friday, Jan. 3, 2014, 11:55 AM ET. The NYSE advances/declines ratio sits at 1,718 issues advancing vs. 1,181 declining with 172 unchanged.

The Drugs industry currently sits up 0.2% versus the S&P 500, which is unchanged. On the negative front, top decliners within the industry include Herbalife ( HLF), down 5.3%, Illumina ( ILMN), down 2.3% and Regeneron Pharmaceuticals ( REGN), down 0.9%. Top gainers within the industry include Novo Nordisk A/S ( NVO), up 1.2%, Novartis ( NVS), up 0.6%, Sanofi ( SNY), up 0.5% and AstraZeneca ( AZN), up 0.5%.

TheStreet would like to highlight 5 stocks pushing the industry lower today:

5. Teva Pharmaceutical Industries ( TEVA) is one of the companies pushing the Drugs industry lower today. As of noon trading, Teva Pharmaceutical Industries is down $0.27 (-0.7%) to $39.99 on light volume. Thus far, 876,631 shares of Teva Pharmaceutical Industries exchanged hands as compared to its average daily volume of 6.5 million shares. The stock has ranged in price between $39.88-$40.38 after having opened the day at $40.27 as compared to the previous trading day's close of $40.26.

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes pharmaceutical products worldwide. Teva Pharmaceutical Industries has a market cap of $33.9 billion and is part of the health care sector. Shares are up 0.5% year to date as of the close of trading on Thursday. Currently there are 5 analysts that rate Teva Pharmaceutical Industries a buy, 3 analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Teva Pharmaceutical Industries as a hold. The company's strengths can be seen in multiple areas, such as its increase in net income, revenue growth and largely solid financial position with reasonable debt levels by most measures. However, as a counter to these strengths, we also find weaknesses including disappointing return on equity, weak operating cash flow and relatively poor performance when compared with the S&P 500 during the past year. Get the full Teva Pharmaceutical Industries Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

4. As of noon trading, Biogen Idec ( BIIB) is down $4.57 (-1.6%) to $275.76 on light volume. Thus far, 215,155 shares of Biogen Idec exchanged hands as compared to its average daily volume of 1.2 million shares. The stock has ranged in price between $275.75-$280.84 after having opened the day at $279.80 as compared to the previous trading day's close of $280.33.

Biogen Idec Inc. discovers, develops, manufactures, and markets therapies for the treatment of neurodegenerative diseases, hemophilia, and autoimmune disorders in the United States and internationally. Biogen Idec has a market cap of $66.0 billion and is part of the health care sector. Shares are unchanged year to date as of the close of trading on Thursday. Currently there are 14 analysts that rate Biogen Idec a buy, no analysts rate it a sell, and 5 rate it a hold.

TheStreet Ratings rates Biogen Idec as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, largely solid financial position with reasonable debt levels by most measures, notable return on equity, reasonable valuation levels and solid stock price performance. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Biogen Idec Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

3. As of noon trading, Amgen ( AMGN) is down $1.28 (-1.1%) to $114.52 on light volume. Thus far, 736,880 shares of Amgen exchanged hands as compared to its average daily volume of 3.0 million shares. The stock has ranged in price between $114.40-$115.97 after having opened the day at $115.70 as compared to the previous trading day's close of $115.80.

Amgen Inc., a biotechnology medicines company, engages in the discovery, development, manufacture, and marketing of human therapeutic products in the areas of supportive cancer care, inflammation, nephrology, and bone diseases primarily in the United States, Europe, and Canada. Amgen has a market cap of $86.0 billion and is part of the health care sector. Shares are unchanged year to date as of the close of trading on Thursday. Currently there are 8 analysts that rate Amgen a buy, no analysts rate it a sell, and 11 rate it a hold.

TheStreet Ratings rates Amgen as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, growth in earnings per share, increase in net income, revenue growth and reasonable valuation levels. We feel these strengths outweigh the fact that the company has had generally high debt management risk by most measures that we evaluated. Get the full Amgen Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

2. As of noon trading, Celgene Corporation ( CELG) is down $2.25 (-1.3%) to $169.69 on light volume. Thus far, 763,230 shares of Celgene Corporation exchanged hands as compared to its average daily volume of 2.7 million shares. The stock has ranged in price between $169.30-$171.79 after having opened the day at $171.49 as compared to the previous trading day's close of $171.94.

Celgene Corporation discovers, develops, and commercializes therapies for cancer and immune-inflammatory related diseases in the United States and Europe. Celgene Corporation has a market cap of $69.6 billion and is part of the health care sector. Shares are up 1.8% year to date as of the close of trading on Thursday. Currently there are 21 analysts that rate Celgene Corporation a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Celgene Corporation as a buy. The company's strengths can be seen in multiple areas, such as its robust revenue growth, expanding profit margins, largely solid financial position with reasonable debt levels by most measures, solid stock price performance and notable return on equity. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full Celgene Corporation Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

1. As of noon trading, Gilead ( GILD) is down $0.76 (-1.0%) to $74.45 on light volume. Thus far, 2.9 million shares of Gilead exchanged hands as compared to its average daily volume of 10.6 million shares. The stock has ranged in price between $74.43-$75.25 after having opened the day at $75.21 as compared to the previous trading day's close of $75.21.

Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes human therapeutics for the treatment of life threatening diseases in North America, Europe, and Asia. Gilead has a market cap of $115.2 billion and is part of the health care sector. Shares are up 0.1% year to date as of the close of trading on Thursday. Currently there are 16 analysts that rate Gilead a buy, no analysts rate it a sell, and 2 rate it a hold.

TheStreet Ratings rates Gilead as a buy. The company's strengths can be seen in multiple areas, such as its revenue growth, solid stock price performance, reasonable valuation levels, expanding profit margins and good cash flow from operations. Although the company may harbor some minor weaknesses, we feel they are unlikely to have a significant impact on results. Get the full Gilead Ratings Report now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

If you are interested in one of these 5 stocks, ETFs may be of interest. Investors who are bullish on the drugs industry could consider SPDR S&P Pharmaceuticals ETF ( XPH) while those bearish on the drugs industry could consider ProShares UltraShort Nasdaq Biotech ( BIS).

null

More from Markets

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Sohn Conference Briefly Distracts From Barrage of Earnings -- ICYMI

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Dow and Nasdaq Finish Lower as 10-Year Treasury Yield Hovers Near 3%

Video: Stop Using Student Loan Money to Buy Bitcoin

Video: Stop Using Student Loan Money to Buy Bitcoin

Let the Najarian Brothers Crash-Proof Portfolio

Let the Najarian Brothers Crash-Proof Portfolio

Facebook Sends Facial Recognition Notification in Error

Facebook Sends Facial Recognition Notification in Error